Gilead Sciences, Inc. Announced The Completion Of The Previously Announced Transaction To Acquire Mirobio, A Privately Held U.K.-Based Biotechnology Company Focused On Restoring Immune Balance With Agonists Targeting Immune Inhibitory Receptors, For Approximately $405 Million In Cash. The Acquisition Provides Gilead With Mirobio
